Using PK/PD to optimize antibiotic dosing for critically ill patients

Current Pharmaceutical Biotechnology

Volumn 12, Issue 12, 2011, Pages 2070-2079

  Roberts, Jason A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Clearance; Pharmacodynamics; Pharmacokinetics; Renal failure; Renal replacement therapy; Volume of distribution

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; CREATININE; LEVOFLOXACIN; LINCOSAMIDE DERIVATIVE; LINEZOLID; MACROLIDE; MEROPENEM; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TIGECYCLINE;

ALGORITHM; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BAYESIAN LEARNING; CAPILLARY PERMEABILITY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; ENDOCARDITIS; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HOSPITAL INFECTION; HUMAN; HYDROPHILICITY; INTENSIVE CARE; INTERSTITIAL FLUID; KIDNEY CLEARANCE; KIDNEY DISEASE; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OPTIMAL DRUG DOSE; PATHOPHYSIOLOGY; PNEUMONIA; RESPIRATORY FAILURE; SEPSIS; SYSTEMATIC REVIEW; TIGHT JUNCTION; TISSUE DISTRIBUTION;

ANIMALS; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 83155166316     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798808329     Document Type: Article

References (76)

1. Drusano, G. L.; Johnson, D. E.; Rosen, M.; Standiford, H. C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother., 1993, 37(3), 483-490.
2. Hosein, S.; Udy, A. A.; Lipman, J. The critically ill patient. Curr. Pharmaceut. Biotech., 2011, 12 in press
3. Roberts, J. A.; Lipman, J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med., 2009, 37(3), 840-851.
4. Finfer, S.; Bellomo, R.; Lipman, J.; French, C.; Dobb, G.; Myburgh, J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med., 2004, 30(4), 589-596.
5. Bone, R. C.; Balk, R. A.; Cerra, F. B.; Dellinger, R. P.; Fein, A. M.; Knaus, W. A.; Schein, R. M.; Sibbald, W. J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. american college of chest physicians/society of critical care medicine. Chest, 1992, 101(6), 1644-1655.
6. Calandra, T.; Cohen, J. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit. Care Med.,2005, 33(7), 1538-1548.
7. Roberts, J. A.; Lipman, J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin. Pharmacokinet., 2006, 45(8), 755-773.
8. Joukhadar, C.; Frossard, M.; Mayer, B. X.; Brunner, M.; Klein, N.; Siostrzonek, P.; Eichler, H. G.; Muller, M. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit. Care Med., 2001, 29(2), 385-391.
9. Roberts, J. A.; Kirkpatrick, C. M. J.; Roberts, M. S.; Robertson, T. A.; Dalley, A. J.; Lipman, J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction - intermittent bolus vs continuous administration? Monte-Carlo dosing simulations and subcutaneous tissue distribution. J. Antimicrob. Chemother., 2009, 64, 142-150.
10. Roberts, J. A.; Roberts, M. S.; Robertson, T. A.; Dalley, A. J.; Lipman, J. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? Crit. Care Med., 2009, 37(3), 926-933.
11. Vinks, A. A.; Brimicombe, R. W.; Heijerman, H. G.; Bakker, W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J. Antimicrob. Chemother., 1997, 40(1), 125-133.
12. Nix, D. E. Intrapulmonary concentrations of antimicrobial agents. Infect. Dis. Clin. N. Am, 1998, 12(3), 631-646, viii.
13. Udy, A. A.; Roberts, J. A.; Boots, R. J.; Paterson, D. L.; Lipman, J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin. Pharmacokinet, 2010, 49(1), 1-16.
14. Pea, F.; Viale, P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin. Infect. Dis., 2006, 42(12), 1764-1771.
15. Gous, A.; Lipman, J.; Scribante, J.; Tshukutsoane, S.; Hon, H.; Pinder, M.; Mathivha, R.; Verhoef, L.; Stass, H. Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. Int. J. Antimicrob. Agents, 2005, 26(1), 50-55.
16. Gous, A. G.; Dance, M. D.; Lipman, J.; Luyt, D. K.; Mathivha, R.; Scribante, J. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth. Intensive Care, 1995, 23(6), 678-682.
17. Ulldemolins, M.; Roberts, J. A.; Rello, J.; Paterson, D. L.; Lipman, J. The effects of hypoalbuminaemia on optimising antibiotic dosing in critically ill patients. Clin. Pharmacokinet, 2010, 50(2),99-110.
18. Joynt, G. M.; Lipman, J.; Gomersall, C. D.; Young, R. J.; Wong, E. L.; Gin, T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J. Antimicrob. Chemother., 2001, 47(4), 421-429.
19. Ulldemolins, M.; Roberts, J. A.; Wallis, S. C.; Rello, J.; Lipman, J. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J. Antimicrob. Chemother., 2010, 65(8), 1771-1778.
20. Brink, A. J.; Richards, G. A.; Cummins, R. R.; Lambson, J. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int. J. Antimicrob. Agents, 2008, 32(5), 455-458.
21. Brink, A. J.; Richards, G. A.; Schillack, V.; Kiem, S.; Schentag, J. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int. J. Antimicrob. Agents, 2009, 33(5), 432-436.
22. Pea, F.; Viale, P.; Furlanut, M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin. Pharmacokinet., 2005, 44(10), 1009-1034.
23. Lipman, J.; Wallis, S. C.; Boots, R. J. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth. Analg., 2003, 97(4), 1149-1154.
24. Lipman, J.; Wallis, S. C.; Rickard, C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob. Agents Chemother., 1999, 43(10), 2559-2561.
25. Lipman, J.; Wallis, S. C.; Rickard, C. M.; Fraenkel, D. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med., 2001, 27(2), 363-370.
26. Choi, G.; Gomersall, C. D.; Tian, Q.; Joynt, G. M.; Freebairn, R. C.; Lipman, J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit. Care Med., 2009, 37(7), 2268-2282.
27. Li, A. M.; Gomersall, C. D.; Choi, G.; Tian, Q.; Joynt, G. M.; Lipman, J. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J. Antimicrob. Chemother., 2009, 64(5), 929-937.
28. Pong, S.; Seto, W.; Abdolell, M.; Trope, A.; Wong, K.; Herridge, J.; Harvey, E.; Kavanagh, B. P. 12-hour versus 24-hour creatinine clearance in critically ill pediatric patients. Pediatr. Res., 2005, 58(1), 83-88.
29. Martin, J. H.; Fay, M. F.; Udy, A. A.; Roberts, J. A.; Kirkpatrick, C. M. J.; Ungerer, J.; Lipman, J. Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Intern. Med. J., 2009, [Epub ahead of print].
30. Joy, M. S.; Matzke, G. R.; Armstrong, D. K.; Marx, M. A.; Zarowitz, B. J. A primer on continuous renal replacement therapy for critically ill patients. Ann. Pharmacother., 1998, 32(3), 362-375.
31. Schetz, M.; Ferdinande, P.; Van den Berghe, G.; Verwaest, C.; Lauwers, P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med., 1995, 21(7), 612-620.
32. Reetze-Bonorden, P.; Bohler, J.; Keller, E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin. Pharmacokinet., 1993, 24(5), 362-379.
33. Tomaselli, F.; Dittrich, P.; Maier, A.; Woltsche, M.; Matzi, V.; Pinter, J.; Nuhsbaumer, S.; Pinter, H.; Smolle, J.; Smolle-Juttner, F. M. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br. J. Clin. Pharmacol., 2003, 55(6), 620-624.
34. Joukhadar, C.; Klein, N.; Dittrich, P.; Zeitlinger, M.; Geppert, A.; Skhirtladze, K.; Frossard, M.; Heinz, G.; Muller, M. Target site penetration of fosfomycin in critically ill patients. J. Antimicrob. Chemother., 2003, 51(5), 1247-1252.
35. Joukhadar, C.; Klein, N.; Mayer, B. X.; Kreischitz, N.; Delle- Karth, G.; Palkovits, P.; Heinz, G.; Muller, M. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit. Care Med., 2002, 30(7), 1478-1482.
36. Boselli, E.; Breilh, D.; Duflo, F.; Saux, M. C.; Debon, R.; Chassard, D.; Allaouchiche, B. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit. Care Med., 2003, 31(8), 2102-2106.
37. Boselli, E.; Breilh, D.; Rimmele, T.; Djabarouti, S.; Toutain, J.; Chassard, D.; Saux, M. C.; Allaouchiche, B. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit. Care Med., 2005, 33(7), 1529-1533.
38. Boselli, E.; Breilh, D.; Rimmele, T.; Guillaume, M.; Xuereb, F.; Saux, M. C.; Bouvet, L.; Chassard, D.; Allaouchiche, B. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit. Care Med., 2008, 36(5),1500-1506.
39. Boselli, E.; Breilh, D.; Rimmele, T.; Poupelin, J. C.; Saux, M. C.; Chassard, D.; Allaouchiche, B. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med., 2004, 30, 989-991.
40. Theuretzbacher, U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr. Opin. Pharmacol., 2007, 7(5), 498-504.
41. Girardi, C.; Tonnellier, M.; Goldstein, I.; Sartorius, A.; Wallet, F.; Rouby, J. J. Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia. Intensive Care Med., 2006, 32(12), 2042-2048.
42. Nicolau, D. P. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J. Infect. Chemother., 2003, 9(4), 292-296.
43. Craig, W. A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis., 1998, 26(1), 1-10; quiz 11-2.
44. Moore, R. D.; Lietman, P. S.; Smith, C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis., 1987, 155, 93-99.
45. Forrest, A.; Nix, D. E.; Ballow, C. H.; Goss, T. F.; Birmingham, M. C.; Schentag, J. J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother., 1993, 37(5), 1073-1081.
46. Rayner, C. R.; Forrest, A.; Meagher, A. K.; Birmingham, M. C.; Schentag, J. J. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin. Pharmacokinet., 2003, 42(15), 1411-1423.
47. McKinnon, P. S.; Paladino, J. A.; Schentag, J. J. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int. J. Antimicrob. Agents, 2008, 31(4), 345-351.
48. Drusano, G. L.; Preston, S. L.; Fowler, C.; Corrado, M.; Weisinger, B.; Kahn, J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis., 2004, 189(9), 1590-1597.
49. Forrest, A.; Chodosh, S.; Amantea, M. A.; Collins, D. A.; Schentag, J. J. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother., 1997, 40 (Suppl A), 45-57.
50. Preston, S. L.; Drusano, G. L.; Berman, A. L. Pharmaco-dynamics of levofloxacin: a new paradigm for early clinical trials. JAMA, 1998, 279, 125-129.
51. Ambrose, P. G.; Grasela, D. M.; Grasela, T. H.; Passarell, J.; Mayer, H. B.; Pierce, P. F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with communityacquired respiratory tract infections. Antimicrob. Agents Chemother., 2001, 45(10), 2793-2797.
52. Lodise, T. P.; Preston, S.; Bhargava, V.; Bryskier, A.; Nusrat, R.; Chapel, S.; Rangaraju, M.; Drusano, G. L. Pharmacodynamics of an 800-mg dose of telithromycin in patients with communityacquired pneumonia caused by extracellular pathogens. Diagn. Microbiol. Infect. Dis., 2005, 52(1), 45-52.
53. Bhavnani, S. M.; Passarell, J. A.; Owen, J. S.; Loutit, J. S.; Porter, S. B.; Ambrose, P. G. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother., 2006, 50(3), 994-1000.
54. Meagher, A. K.; Passarell, J. A.; Cirincione, B. B.; Van Wart, S. A.; Liolios, K.; Babinchak, T.; Ellis-Grosse, E. J.; Ambrose, P. G. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob. Agents Chemother., 2007, 51(6), 1939-1945.
55. Passarell, J. A.; Meagher, A. K.; Liolios, K.; Cirincione, B. B.; Van Wart, S. A.; Babinchak, T.; Ellis-Grosse, E. J.; Ambrose, P. G. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob. Agents Chemother., 2008, 52(1), 204-210.
56. Li, C.; Du, X.; Kuti, J. L.; Nicolau, D. P. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob. Agents Chemother., 2007, 51(5), 1725-1730.
57. Ariano, R. E.; Nyhlen, A.; Donnelly, J. P.; Sitar, D. S.; Harding, G. K.; Zelenitsky, S. A. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann. Pharmacother., 2005, 39(1), 32-38.
58. Dailey, C. F.; Dileto-Fang, C. L.; Buchanan, L. V.; Oramas-Shirey, M. P.; Batts, D. H.; Ford, C. W.; Gibson, J. K. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillinresistant Staphylococcus aureus. Antimicrob. Agents Chemother., 2001, 45(8), 2304-2308.
59. Jumbe, N.; Louie, A.; Leary, R.; Liu, W.; Deziel, M. R.; Tam, V. H.; Bachhawat, R.; Freeman, C.; Kahn, J. B.; Bush, K.; Dudley, M. N.; Miller, M. H.; Drusano, G. L. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest., 2003, 112(2), 275-285.
60. Lodise, T. P. Jr.; Lomaestro, B.; Drusano, G. L. Piperacillintazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis., 2007, 44(3), 357-363.
61. Roberts, J. A.; Kruger, P.; Paterson, D. L.; Lipman, J. Antibiotic resistance-what's dosing got to do with it? Crit. Care Med., 2008, 36(8), 2433-2440.
62. Spellberg, B.; Guidos, R.; Gilbert, D.; Bradley, J.; Boucher, H. W.; Scheld, W. M.; Bartlett, J. G.; Edwards, J. Jr. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis., 2008, 46(2), 155-164.
63. van Lent-Evers, N. A.; Mathot, R. A.; Geus, W. P.; van Hout, B. A.; Vinks, A. A. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther. Drug Monit., 1999, 21(1), 63-73.
64. Scaglione, F.; Esposito, S.; Leone, S.; Lucini, V.; Pannacci, M.; Ma, L.; Drusano, G. L. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur. Respir. J., 2009, 34(2), 394-400.
65. Bracco, D.; Landry, C.; Dubois, M. J.; Eggimann, P. Pharmacokinetic variability of extended interval tobramycin in burn patients. Burns, 2008, 34(6),791-796.
66. Tang, G. J.; Tang, J. J.; Lin, B. S.; Kong, C. W.; Lee, T. Y. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand, 1999, 43(7), 726-730.
67. Mann, H. J.; Fuhs, D. W.; Awang, R.; Ndemo, F. A.; Cerra, F. B. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin. Pharm., 1987, 6(2), 148-153.
68. Roberts, J. A.; Kirkpatrick, C. M.; Roberts, M. S.; Dalley, A. J.; Lipman, J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int. J. Antimicrob. Agents, 2010, 35(2), 156-163.
69. Barbot, A.; Venisse, N.; Rayeh, F.; Bouquet, S.; Debaene, B.; Mimoz, O. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med., 2003, 29(9), 1528-1534.
70. Llopis-Salvia, P.; Jimenez-Torres, N. V. Population pharmacokinetic parameters of vancomycin in critically ill patients. J. Clin. Pharm. Ther., 2006, 31(5), 447-454.
71. Buerger, C.; Plock, N.; Dehghanyar, P.; Joukhadar, C.; Kloft, C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob. Agents Chemother., 2006, 50(7), 2455-2463.
72. Rebuck, J. A.; Fish, D. N.; Abraham, E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy, 2002, 22(10), 1216-1225.
73. Stass, H. Distribution and Tissue Penetration of Moxifloxacin. Drugs, 1999, 58(Suppl 2), 229-230.
74. Meagher, A. K.; Ambrose, P. G.; Grasela, T. H.; Ellis-Grosse, E. J. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis., 2005, 41 (Suppl 5), S333-340.
75. Mann, H. J.; Townsend, R. J.; Fuhs, D. W.; Cerra, F. B. Decreased hepatic clearance of clindamycin in critically ill patients with sepsis. Clin. Pharm., 1987, 6(2), 154-159.
76. Roberts, J.A.; Ulldemolins, M.; Roberts, M.S.; McWhinney, B.C.; Ungerer, J.P.J.; Paterson, D.L.; Lipman, J. Therapeutic Drug Monitoring of Beta-lactams in Critically Ill Patients: Proof of concept. Int. J. Antimicrob. Agents, 2010, 36(4): 332-9.